羊膜腔内反义寡核苷酸治疗改善脊髓性肌萎缩临床前模型表型
研究提出羊膜腔注射反义寡核苷酸(ASO)可安全分布至胎儿中枢神经系统并治疗脊髓性肌萎缩(SMA)。在两种严重SMA小鼠模型中,羊膜腔注射ASO增加中枢神经系统SMN表达;SMAΔ7小鼠产前治疗较出生后(P1至P3)治疗改善运动神经元数量、运动轴突发育、运动行为测试和生存。在胎羊中,妊娠中期羊膜腔或颅内注射ASO后,羊膜腔注射的ASO以治疗浓度分布至脊髓和多个外周组织,未见对胎儿或母体明显毒性。
要点
- 羊膜腔注射ASO可分布至胎儿中枢神经系统,在两种严重SMA小鼠模型中增加SMN表达。
- SMAΔ7小鼠产前治疗较出生后(P1至P3)治疗改善运动神经元数量、运动轴突发育、运动行为测试和生存。
- 胎羊妊娠中期羊膜腔注射ASO后,脊髓达治疗浓度并分布至多个外周组织,未见对胎儿或母体明显毒性。
核心结论
- 羊膜腔递送ASO有望作为微创方法用于SMA及可能的其他严重早发型神经疾病的产前治疗。
研究设计与样本
- 在两种严重SMA小鼠模型中经羊膜腔注射ASO,并与出生后(P1至P3)治疗比较。
- 在胎羊妊娠中期经羊膜腔或颅内注射ASO以评估大动物模型产前治疗的可行性。
主要发现
- 羊膜腔注射ASO在两种严重SMA小鼠模型的中枢神经系统中增加SMN表达。
- SMAΔ7小鼠产前治疗较出生后(P1至P3)治疗改善运动神经元数量、运动轴突发育、运动行为测试和生存。
- 胎羊羊膜腔注射的ASO以治疗浓度分布至脊髓并分布至多个外周组织,未见对胎儿或母体明显毒性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurological disorders with onset before or at birth are a leading cause of morbidity and mortality in infants and children. Prenatal treatment has the potential to reduce or prevent irreversible neuronal loss and facilitate normal neurodevelopment. We hypothesized that antisense oligonucleotides (ASOs) delivered to the amniotic fluid by intra-amniotic (IA) injection could safely distribute to the fetal central nervous system (CNS) and provide therapeutic benefit in the motor neuron disease spinal muscular atrophy (SMA), caused by mutations of the survival of motor neuron 1 gene (SMN1), leading to deficiency of SMN protein. Although the splice-switching ASO nusinersen ameliorates SMA when delivered postnatally, substantial deficits can remain in severely affected infants. Here, IA injection of ASOs into two mouse models of severe SMA increased SMN expression in the CNS. In SMAΔ7 mice, which manifest pathology in utero, prenatal treatment improved motor neuron numbers, motor axon development, motor behavioral tests, and survival when compared with those in mice treated postnatally (between P1 and P3). To assess the feasibility of prenatal treatment in a large-animal model, ASOs were delivered midgestation to fetal sheep by IA or intracranial injection. ASOs delivered by IA injection distributed to the spinal cord at therapeutic concentrations and to multiple peripheral tissues without evidence of substantial toxicity to the fetus or mother. These data demonstrated that IA delivery of ASOs holds potential as a minimally invasive approach for prenatal treatment of SMA and possibly other severe, early-onset neurological disorders.
引用
- Borges B, Brown SM, Chen WJ, et al. Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy. Sci Transl Med. 2025. PMID: 40367190. doi:10.1126/scitranslmed.adv4656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。